Shares of Endo International were down 11% Wednesday after the company said its uses independent specialty pharmacies to sell some of its U.S. products. The amount of revenue that goes through those pharmacies is about 3% of the company’s projected 2015 revenues. The announcement comes in the wake of a short-seller’s report alleging that Valeant Pharmaceuticals International Inc. has a secret relationship with a subsidiary|http://www.marketwatch.com/story/valeant-stock-craters-as-short-seller-alleges-company-faked-sales-2015-10-21] to which it ships product before falsely claiming revenue. Valeant denied the report. Endo said the specialty pharmacies it uses are independent of the company and it does not have any ownership in them.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News